Mutation site and context dependent effects of ESR1 mutation in genome-edited breast cancer cell models

od Bahreini, Amir, Li, Zheqi, Wang, Peilu, Levine, Kevin M., Tasdemir, Nilgun, Cao, Lan, Weir, Hazel M., Puhalla, Shannon L., Davidson, Nancy E., Stern, Andrew M., Chu, David, Park, Ben Ho, Lee, Adrian V., Oesterreich, Steffi
Izdano u Breast Cancer Res (2017)

The oral selective oestrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistance

od Nardone, Agostina, Weir, Hazel, Delpuech, Oona, Brown, Henry, De Angelis, Carmine, Cataldo, Maria Letizia, Fu, Xiaoyong, Shea, Martin J., Mitchell, Tamika, Veeraraghavan, Jamunarani, Nagi, Chandandeep, Pilling, Mark, Rimawi, Mothaffar F., Trivedi, Meghana, Hilsenbeck, Susan G., Chamness, Gary C., Jeselsohn, Rinath, Osborne, C. Kent, Schiff, Rachel
Izdano u Br J Cancer (2018)

Activating ESR1 mutations differentially impact the efficacy of ER antagonists

od Toy, Weiyi, Weir, Hazel, Razavi, Pedram, Lawson, Mandy, Goeppert, Anne U, Mazzola, Anne Marie, Smith, Aaron, Wilson, Joanne, Morrow, Christopher, Wong, Wai Lin, De Stanchina, Elisa, Carlson, Kathryn E., Martin, Teresa S., Uddin, Sharmeen, Li, Zhiqiang, Fanning, Sean, Katzenellenbogen, John A., Greene, Geoffrey, Baselga, Jośe, Chandarlapaty, Sarat
Izdano u Cancer Discov (2016)

Effective combination therapies in preclinical endocrine resistant breast cancer models harboring ER mutations

od Ladd, Brendon, Mazzola, Anne Marie, Bihani, Teeru, Lai, Zhongwu, Bradford, James, Collins, Michael, Barry, Evan, Goeppert, Anne U., Weir, Hazel M., Hearne, Kelly, Renshaw, Jonathan G., Mohseni, Morvarid, Hurt, Elaine, Jalla, Sanjoo, Bao, Haifeng, Hollingsworth, Robert, Reimer, Corinne, Zinda, Michael, Fawell, Stephen, D'Cruz, Celina M.
Izdano u Oncotarget (2016)